BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myelocytic leukemia (CML), inhibition of the MUC1-C oncoprotein disrupts redox balance and thereby 1) decrease break-point cluster region protein (BCR)/Tyrosine-protein kinase (ABL) levels, 2) downregulate β-catenin expression, and 3) induce terminal myeloid cell differentiation, thus avoid CML to enter the acute phase47.